Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

Chaos and Questions: New Public-Access Policies Put Journals in Flux

News Features

Chaos and Questions: New Public-Access Policies Put Journals in Flux

Michael O'Riordan

August 14, 2023

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

News Features

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

January 13, 2022

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

Roughly 80% of ESC Guideline Writers Have Financial COIs

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

News Features

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

February 08, 2021

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

News Features

Tragedy as Catalyst: How COVID-19 May Transform Clinical Research for Good

December 14, 2020

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

News Features

Too Easy to Misconstrue: Is It Time to Ditch Periprocedural MI?

Michael O'Riordan

December 02, 2020

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

News Features

Hospitals Plan Cautious Restart to Elective Procedures as COVID-19 Wanes

Michael O'Riordan

May 12, 2020

Stroke ‘Surge’ in the Young Fuels Debate Over COVID-19’s Culpability

News Features

Stroke ‘Surge’ in the Young Fuels Debate Over COVID-19’s Culpability

May 08, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Top News in Endovascular Therapy: 2018

News Features

Top News in Endovascular Therapy: 2018

December 28, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

Getting High: The Low-down for Cardiologists on Illicit Drugs and Marijuana

News Features

Getting High: The Low-down for Cardiologists on Illicit Drugs and Marijuana

July 13, 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.